The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH

NACompletedINTERVENTIONAL
Enrollment

723

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
DiabetesChronic Kidney DiseaseEstablished Atherosclerotic Vascular DiseaseFramingham Risk Score More Than 20 Percent
Interventions
OTHER

Advanced Care

"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~ * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."

Trial Locations (1)

T6G 2M8

EPICORE Centre, Edmonton

All Listed Sponsors
collaborator

Alberta Health & Wellness

OTHER_GOV

collaborator

Alberta Health services

OTHER

collaborator

Merck Frosst Canada Ltd.

INDUSTRY

lead

University of Alberta

OTHER

NCT01979471 - The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH | Biotech Hunter | Biotech Hunter